Moberg Derma is a Swedish pharmaceutical company that focuses on topical products for skin diseases. In autumn 2010 Moberg Derma initiated the launch of its first products: Emtrix for damaged nails and Kaprolac for dandruff problems.
Moberg Derma's products are based on innovative technology that delivers proven substances in a new way. This strategy reduces time to market, development costs and risk. The company is working on several additional pharmaceutical projects, including nail fungus (onychomycosis) and actinic keratosis. In addition to internal inventions, the portfolio includes acquired and in-licensed projects.